SCHEMBL30296282

SCHEMBL30296282

O=[N+]([O-])c1cc(Cl)c(F)cc1Oc1ccc2nonc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MERTK Q12866 1/20 0.42
▸ EPAS1 Q99814 4/20 0.41
▸ ARNT P27540 3/20 0.41
▸ HSPB1 P04792 2/20 0.40
▸ PDE7A Q13946 1/20 0.39
▸ MAPT P10636 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ TTR P02766 1/20 0.36
▸ PPOX P50336 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ IDO1 P14902 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CRHBP P24387 1/20 0.35
▸ CRHR2 Q13324 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30296294 1.00 MERTK (0.42) MERTKEPAS1ARNTHSPB1PDE7A
SCHEMBL26132877 0.91 ARNT (0.39) MERTKEPAS1ARNTHSPB1PDE7A
SCHEMBL11007687 0.81 PDE7A (0.60) HSPB1PDE7AMAPTSMN1; SMN2TDP1
SCHEMBL30296504 0.79 HTR2A (0.35) EPAS1MAPTSMN1; SMN2LMNAHPGD
SCHEMBL30050147 0.77 MAPT (0.49) MERTKHSPB1PDE7AMAPTSMN1; SMN2
SCHEMBL30296710 0.74 MPO (0.38) EPAS1MAPTSMN1; SMN2LMNAHPGD
SCHEMBL11017217 0.72 PIN1 (0.44) MERTKEPAS1ARNTPDE7AMAPT
SCHEMBL30050734 0.70 MERTK (0.37) MERTKEPAS1HSPB1PDE7AMAPT
SCHEMBL29197501 0.70 GRM5 (0.38) MERTKEPAS1HSPB1PDE7AMAPT
SCHEMBL30879410 0.69 ALDH1A1 (0.46) HSPB1PDE7AMAPTSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 — — US disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 — — EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 — — CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 MERTK 2150/4885EPAS1 1790/4885ARNT 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback